Abnormalities, Multiple: Clinical Trials

2 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Active not recruiting 2

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Empagliflozin 10 MG, Placebo - Autosomal Dominant Polycystic Kidney
Phase 4Active not recruitingHannover Medical School442024-06-142025-11-24
Statin Therapy in Patients With Early Stage ADPKD
Pravastatin, Placebo - ADPKD, Autosomal Dominant Polycystic Kidney
Phase 4Active not recruitingUniversity of Colorado, Denver1502017-08-312025-05-08

Narrower conditions

Polycystic Kidney, Autosomal Dominant (2)

Broader conditions

Ciliopathies (2)  ·  Congenital Abnormalities (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genetic Diseases, Inborn (2)  ·  Kidney Diseases (2)  ·  Kidney Diseases, Cystic (2)  ·  Male Urogenital Diseases (2)  ·  Polycystic Kidney Diseases (2)  ·  Urogenital Diseases (2)  ·  Urologic Diseases (2)

Interventions

Pravastatin (1)  ·  empagliflozin (1)

Sponsors

Hannover Medical School (1)  ·  University of Colorado, Denver (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Michel Chonchol, MD (1)

Results publications

PMID 39356039, PMID 38151173, PMID 39675824, PMID 40377984, PMID 41077128

NIH funding

2023 (1)